diffusion pharmaceuticals 예문

예문

예문 더보기:   1  2

1. It was through his association with the University of Virginia that Kalergis met Gainer, who was at that time a Professor of Chemical Engineering, leading to their collaboration in the founding of Diffusion Pharmaceuticals.
2. The developer of oxygen diffusion-enhancing compounds, Diffusion Pharmaceuticals, tested its lead compound, trans sodium crocetinate ( TSC ), in a Phase II clinical trial in 59 patients newly diagnosed with glioblastoma multiforme.
3. TSC, which is being developed by Diffusion Pharmaceuticals, has been shown to enhance the oxygenation of hypoxic tumor tissue and belongs to a subclass of oxygen diffusion-enhancing compounds known as bipolar trans carotenoid salts.
4. TSC and other oxygen diffusion-enhancing compounds, including bipolar trans carotenoid salts ( the subclass to which TSC belongs ), have been investigated by Diffusion Pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues ( hypoxia ).
5. The drug has also been under investigation in a clinical trial sponsored by drug developer Diffusion Pharmaceuticals for potential use as a radiosensitizer, increasing the susceptibility of hypoxic cancer cells to radiation therapy, in patients with a form of brain cancer known as glioblastoma.